Antibe Therapeutics Stock Total Debt
| ATBPF Stock | USD 0.22 0.00 0.00% |
Antibe Therapeutics fundamentals help investors to digest information that contributes to Antibe Therapeutics' financial success or failures. It also enables traders to predict the movement of Antibe Pink Sheet. The fundamental analysis module provides a way to measure Antibe Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Antibe Therapeutics pink sheet.
Antibe |
Antibe Therapeutics Company Total Debt Analysis
Antibe Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Antibe Therapeutics Total Debt | 205 K |
Most of Antibe Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Antibe Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Antibe Therapeutics has a Total Debt of 205 K. This is 99.99% lower than that of the Pharmaceuticals sector and 99.99% lower than that of the Health Care industry. The total debt for all United States stocks is 100.0% higher than that of the company.
Antibe Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Antibe Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Antibe Therapeutics could also be used in its relative valuation, which is a method of valuing Antibe Therapeutics by comparing valuation metrics of similar companies.Antibe Therapeutics is currently under evaluation in total debt category among its peers.
Antibe Fundamentals
| Return On Equity | -0.4 | |||
| Return On Asset | -0.16 | |||
| Current Valuation | (19.98 M) | |||
| Shares Outstanding | 52.14 M | |||
| Shares Owned By Insiders | 7.79 % | |||
| Price To Earning | (1.67) X | |||
| Price To Book | 0.61 X | |||
| Price To Sales | 2.96 X | |||
| Gross Profit | 3.55 M | |||
| EBITDA | (25.14 M) | |||
| Net Income | (25.06 M) | |||
| Cash And Equivalents | 50.19 M | |||
| Cash Per Share | 0.96 X | |||
| Total Debt | 205 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 14.65 X | |||
| Book Value Per Share | 0.90 X | |||
| Cash Flow From Operations | (16.92 M) | |||
| Earnings Per Share | (0.41) X | |||
| Target Price | 4.53 | |||
| Number Of Employees | 37 | |||
| Beta | 0.0997 | |||
| Market Capitalization | 22.59 M | |||
| Total Asset | 89.16 M | |||
| Retained Earnings | (12.08 M) | |||
| Working Capital | 1.45 M | |||
| Current Asset | 3.96 M | |||
| Current Liabilities | 2.51 M | |||
| Z Score | 66.0 | |||
| Net Asset | 89.16 M |
About Antibe Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Antibe Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Antibe Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Antibe Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Antibe Pink Sheet
Antibe Therapeutics financial ratios help investors to determine whether Antibe Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antibe with respect to the benefits of owning Antibe Therapeutics security.